Cipla Q4 FY26 Results Preview: Largecap drug maker's PAT likely to slump 40%, margin set to fall by 8%

Mumbai-headquartered Cipla is scheduled to report its financial results for the quarter as well as the year ended March 31 on Wednesday, May 13. Analysts expect the drug maker to stage a weak performance for the final three months of FY26 with a significant fall in its US operations.

Cipla Q4 FY26 Results Preview: Headline number estimates

According to Zee Business research, Cipla is estimated to register a consolidated net profit of Rs 746 crore for the January-March period, which translates to a year-on-year fall of 40 per cent.

Its top line is estimated to grow 0.5 per cent on a year-on-year basis to Rs 6,763 crore.

Operational performance

Cipla -- the country's fifth largest pharma company by market value and fourth largest by sales -- is estimated to register March-quarter earnings before interest, depreciation and amortisation (EBITDA) of Rs 1,085 crore. This marks a 29 per cent year-on-year fall.

Its quarterly margin is pegged at 16 per cent versus 23 per cent a year ago.

Other things to watch out for

The pharma firm's America business is estimated to fall 24-30 per cent on a year-on-year basis, with nil contribution from gRevlimid -- an immunomodulatory drug prescribed in the treatment of blood cancers.

Cipla manufactures and markets a generic version of the the drug.

Analysts anticipate disruptions in the supply of gLanreotide to impact the company's sales in the region.

Cipla Q3 FY26 results

For the quarter ended December 31, the drug maker reported a 57 per cent year-on-year fall in its net profit to Rs 676 crore, while its revenue remained nearly unchanged at Rs 7,074 crore from Rs 7,073 crore a year ago.

Its third-quarter EBITDA fell 36.9 per cent to Rs 1,255 crore, according to an investor presentation.

The company's India business clinched a 10 per cent increase in revenue to Rs 3,457 crore, while revenue from its North America operations fell 22 per cent to Rs 1,485 crore.

Revenue from emerging markets and Europe increased 13 per cent to Rs 929 crore, according to the company.

Its API unit registered a 15 per cent jump in revenue to Rs 144 crore.

ALSO READ: Is it a good time to buy Biocon shares on Dalal Street? Key takeaways from Q4 FY26 results

Cipla share price vs Nifty 50 vs Nifty Pharma

As of May 12, Cipla shares have lost 13.8 per cent of their value so far this year, while the Nifty 50 and Nifty Pharma indices have fallen 10.6 per cent and risen 5.3 per cent, respectively.

The stock is down 14.4 per cent in a year. The 50-scrip headline index has declined 6.20 per cent during this period, while the pharma gauge has risen 13 per cent.

Healthcare stocks have a weightage of 4.5 per cent in the Nifty 50, whereas Cipla's weightage stands at less than one per cent.

Cipla is among the 20 Nifty Pharma constituents, holding a weightage of 8.7 per cent in the sectoral index.